However, recent research indicates a concerning trend: approximately 50% of individuals prescribed these second-line therapies discontinue their usage within a year
Pregnant or breastfeeding women should not use the drug
Semaglutide Injection runs $2,268/year ($189/mo across five dose levels), Tirzepatide Injection runs $3,468/year ($289/mo across six dose levels), and GLP-Squared dual-compound runs $3,468/year ($289/mo)
Cognition and synaptic-plasticity related changes in aged rats supplemented with 8- and 10-carbon medium chain triglycerides
Better Energy Levels: A controlled approach helps maintain higher energy levels, which is crucial for staying active and preserving lean muscle mass
Association Between GLP-1 Receptor Agonists and Incidence of Lung Cancer in Treatment-Naive Type 2 Diabetes